← Evidence map

ArticleESMO open2022

Corrigendum to "How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain": [ESMO Open, 7 (2022) 100462].

A Castañeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Corrigendum to "How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain": [ESMO Open, 7 (2022) 100462]. | OpenQuestion